Conference call and webcast to be held at 8 a.m. ET on January 7, 2026BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will host a live conference call and webcast on Wednesday, January 7, at 8:00 a.m. ET. The webcast presentation will highlight interim clinical results from the ongoing Phase 1 study of the NEK7-directed MGD MRT-8102, i ...

Core Insights - Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel molecular glue degrader (MGD)-based medicines for serious diseases [2] Company Overview - Monte Rosa specializes in highly selective MGD medicines targeting oncology, autoimmune, and inflammatory diseases [2] - The company utilizes its QuEEN™ discovery engine, which integrates AI-guided chemistry, diverse chemical libraries, structural biology, and proteomics to design MGDs with high selectivity [2] - Monte Rosa has established a leading pipeline of MGDs and holds a global license agreement with Novartis for VAV1-directed molecular glue degraders [2] - The company has a strategic collaboration with Roche to discover and develop MGDs for cancer and neurological diseases [2] Upcoming Events - Monte Rosa will participate in the Morgan Stanley 23 Annual Global Healthcare Conference on September 8, 2025 [3] - The company will also take part in the Stifel 2025 Virtual Immunology and Inflammation Forum on September 15, 2025, featuring a fireside chat with CEO Markus Warmuth [3]